News | Nuclear Imaging | November 07, 2018

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine

New market report notes that approximately $10 billion in M&A transactions have occurred over the past four years, with signs indicating continuing future growth

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine

November 7, 2018 — With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry towards radiopharmaceuticals and in particular radiotherapeutics and radiotheranostics is clearly growing, as foreseen a few years ago by MEDraysintell.

Numerous major acquisitions have involved the conventional pharmaceutical industry over the past four years:

  • In 2014, Bayer acquired Algeta ASA and its major drug for end-stage prostate cancer treatment 223Ra-Xofigo for about NOK 17.6 billion ($2.9 billion), while Novartis took over Advanced Accelerator Applications (AAA) and its Neuro Endocrine Tumor treatment 177Lu-Lutathera in January 2018 for a total value of $3.9 billion;
  • Additionally Novartis announced in October 2018 the acquisition of the company Endocyte developing the prostate cancer drug 177Lu-PSMA-617 for a total value of $2.1 billion. This transaction is expected to be completed in the first half of 2019.
  • Ipsen Pharma acquired in May 2015 the German company OctreoPharm Sciences GmbH, for a total of EUR 50 million (about $55 million) and one year later a large part of the radiopharmaceutical pipeline of the German company 3B Pharmaceuticals GmbH; and
  • Sun Pharmaceutical Industries acquired Pharmalucence in July 2014 for an undisclosed amount.

MEDraysintell noted that other mergers within the radiopharmaceutical industry showed consolidation of this industry:

  • IBA Molecular acquired the Nuclear Medicine business of Mallinckrodt in January 2017 for a total of about $690 million;
  • Jubilant Draximage acquired the Triad Isotopes radiopharmacy network in May 2017; and
  • Sofie Biosciences took over Zevacor Pharma in May 2017.

The company said there are great chances that additional mergers and acquisitions (M&A) will take place within the next 12 months. At the same time, the conventional pharmaceutical industry is now looking for new opportunities in early-stage research programs in this area. MEDraysintell anticipates that the global market will reach $5.9 billion in 2019, and it is now expected that radiotherapeutics will represent more than 60 percent of the $26 billion nuclear medicine market by 2030.

Most of the development of new radiopharmaceuticals is performed by new medium-sized radiopharmaceuticals companies and conventional pharmaceutical corporations. MEDraysintell said these companies are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2018.

For more information: www.medraysintell.com

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging | September 03, 2021
September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Maste
ASTRO’s 63rd Annual Meeting is scheduled to take place as an in-person meeting October 24-27 in Chicago, but be sure to bring along your masks

Getty Images

News | ASTRO | August 11, 2021
August 11, 2021 — ASTRO announced that it is facilitating measu
Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory

Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory

News | PET Imaging | August 06, 2021
August 6, 2021 — A multidisciplinary tea...
PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, pet scanner, nuclear imaging, molecular imaging

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

News | PET-CT | August 04, 2021
August 4, 2021 — PET/CT systems are exp
The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R. 4479, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021” by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).

Getty Images

News | Nuclear Imaging | August 04, 2021
August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc.